Repligen Sets October 5 Vote on $1.5B BioLife Acquisition
RGEN sits 66% above its 52-week low of $100.99.
Summary
Repligen's definitive proxy statement sets the October 5, 2026 BioLife stockholder vote on the $1.5 billion acquisition, with the HSR waiting period having expired on September 3, 2026.
Key Events · M&A and Partnerships · RGEN
-
Special Meeting Set for October 5
BioLife stockholders of record as of September 3, 2026 will vote on the merger agreement at a virtual special meeting on October 5, 2026. Approval requires a majority of outstanding shares.
-
HSR Waiting Period Expired
The HSR waiting period was scheduled to expire at 11:59 p.m. Eastern Time on September 3, 2026, clearing a key U.S. antitrust hurdle for the transaction.
-
Competing Bids Revealed
The background section discloses that Party A submitted proposals up to $29.50 per share and Party C submitted a $30.00 per share all-cash proposal, both of which were ultimately not pursued.
-
Golden Parachute Compensation Disclosed
BioLife named executive officers could receive approximately $52.2 million in total golden parachute compensation, including $28.9 million for CEO Roderick de Greef.
Analysis · RGEN · Life Sciences
This definitive proxy statement/prospectus finalizes the timeline for Repligen's $1.5 billion acquisition of BioLife Solutions. BioLife stockholders will vote on October 5, 2026, with a record date of September 3, 2026. The HSR waiting period expired on September 3, 2026, clearing a key regulatory hurdle. The filing also reveals the full negotiation history, including competing bids from two other parties, and discloses approximately $52.2 million in golden parachute compensation for BioLife executives. The deal remains on track for a Q4 2026 close.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGEN was trading at $167.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $100.99 to $188.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.